Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503583 | 0.91 | KDM1A (0.53) | GRIN2BDRD4KDM1AEHMT2HDAC6 | |
| SCHEMBL4509574 | 0.81 | HSD17B10 (0.44) | DRD4HDAC6HDAC1HDAC8 | |
| SCHEMBL4514349 | 0.80 | GRIN2B (0.56) | GRIN2BKCNH2 | |
| SCHEMBL4496490 | 0.73 | HDAC6 (0.41) | EHMT2HDAC6HTR1A | |
| SCHEMBL4497481 | 0.72 | SMN1; SMN2 (0.44) | DRD4KDM1AHDAC6MAOBHDAC1 | |
| SCHEMBL5391813 | 0.71 | RAF1 (0.62) | — | |
| SCHEMBL4504235 | 0.71 | PTGER4 (0.49) | — | |
| SCHEMBL4505044 | 0.71 | ACHE (0.42) | DRD4HDAC6HDAC1HDAC8 | |
| SCHEMBL4496634 | 0.70 | MAPT (0.47) | — | |
| SCHEMBL13991772 | 0.70 | SMN1; SMN2 (0.56) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | GRIN2B 2189/4885HRH1 22/4885DRD4 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.